BL-5010 Earns CE Mark

BioLineRx’s partner Omega Pharma, a unit of Perrigo, has received CE marking for BL-5010 as a novel OTC treatment for the noninvasive removal of skin lesions.

BioLineRx — an Israeli biopharmaceutical company — holds the global OTC rights to BL-5010, in addition to global rights for non-OTC indications. 

Compared with traditional skin lesion removal methods, the Class 2a medical device reduces infection risk and removes the need for anesthesia or bandaging, BioLineRx says.

A commercial launch is expected by mid-2016. — Anisa Jibrell